Glaukos Corneal Health

Glaukos has acquired Avedro, Inc., for all future updates please follow @glaukos-corporation http://investors.glaukos.com/investors/press-releases/press-release-details/2019/Glaukos-Completes-Acquisition-of-Avedro-Inc/default.aspx We are focused on pioneering new treatments for chronic eye diseases. At Glaukos, our focus is to develop and lead the global ophthalmic market with novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases—therapies that advance the existing standard of care and enrich the lives and treatment alternatives for patients worldwide.